Mark Bach
Chief Tech/Sci/R&D Officer bei STRUCTURE THERAPEUTICS INC.
Vermögen: 61 712 $ am 31.03.2024
Profil
Dr. Mark A. Bach, MD, ist Senior Vice President-Klinische Entwicklung bei Ascendis Pharma A/S. Dr. Bach war zuvor als Chief Executive Officer bei Accumulus Synergy, Inc, als Head-Asia Pacific Medical Sciences bei Janssen Pharmaceuticals, Inc, als Vice President-Research & Development bei Janssen Pharmaceutical KK und als VP-Clinical Research Operations Worldwide bei Merck & Co, Inc. tätig. Er erhielt seinen Bachelor-Abschluss am Carleton College, einen Doktortitel von der University of Chicago und einen Doktortitel vom Baylor College of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.03.2024 | 4 320 ( 0,00% ) | 61 712 $ | 31.03.2024 |
Aktive Positionen von Mark Bach
| Unternehmen | Position | Beginn |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01.06.2021 |
Ehemalige bekannte Positionen von Mark Bach
| Unternehmen | Position | Ende |
|---|---|---|
| Accumulus Synergy, Inc | Chief Executive Officer | 01.10.2020 |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | 01.08.2019 |
Janssen Pharmaceutical KK
 Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Chief Tech/Sci/R&D Officer | 01.11.2012 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01.01.2010 |
| ASCENDIS PHARMA A/S | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Mark Bach
| Carleton College | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
| Baylor College of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| STRUCTURE THERAPEUTICS INC. | Commercial Services |
| Private Unternehmen | 3 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Janssen Pharmaceutical KK
Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Health Technology |
| Accumulus Synergy, Inc |
